Canine interferon α particle complex and its preparation method and application

A technology of canine interferon and α particles, which is applied in the direction of pharmaceutical formulas, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., to achieve the effects of good biocompatibility, slow down degradation, and mild preparation conditions

Active Publication Date: 2017-01-11
EAST CHINA NORMAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the prior art, nano-medicines are mostly anti-tumor drugs and other human drugs, and there are no reports of their application in canine anti-viral drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Canine interferon α particle complex and its preparation method and application
  • Canine interferon α particle complex and its preparation method and application
  • Canine interferon α particle complex and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1P

[0030] Example 1 Synthesis of PGA-PAE material

[0031] Weigh 0.1 g of γ-polyglutamic acid and dissolve it in 5 ml of pure water to prepare a 2% PGA solution. The pH of the PGA solution was adjusted to 3.0 with 1 mol / L hydrochloric acid. The PGA solution was put into a 98°C water bath for degradation for 11 min, and the temperature was cooled in an ice bath immediately after the degradation. The pH was then adjusted to 7.0 with 1 mol / L sodium hydroxide solution. 0.297 g of EDC.I and 0.146 g of ethyl phenylalanine were added sequentially. The reaction was carried out on a shaker at 37°C and 210rpm for 24h. After the reaction, the reaction system was centrifuged at 12,000 rpm for 1 min, and the precipitate was resuspended with pure water. Repeat centrifugation 2 times. Dry the white precipitate. Weighing, dissolving the precipitate with dimethyl sulfoxide, and making up to 40 mg / ml, the PGA-PAE material is obtained.

Embodiment 2

[0032] Example 2 Preparation of canine interferon alpha particle complex CaIFNα-NPs encapsulated and fused with canine interferon alpha

[0033] Take 1ml of the above PGA-PAE material, slowly drop it into 1ml of 0.25mg / ml fused canine interferon alpha aqueous solution, and mix to obtain a white emulsion. The emulsion was centrifuged at 16000 rpm for 15 min. The pellet was separated from the supernatant. The pellet was resuspended with 2 ml of pure water and centrifuged again at 16000 rpm for 15 min. The precipitate was separated from the supernatant, and the precipitate was lyophilized to obtain CaIFNα-NPs.

[0034] Wherein, the sequence of the fusion canine interferon alpha is shown in SEQ ID No: 1.

[0035] In order to verify whether the fusion canine interferon alpha was encapsulated into the particles and to calculate the encapsulation rate of the fusion canine interferon alpha, CaIFNα-NPs were cleaved with 4% sodium dodecyl sulfonate solution. Since CaIFNα-NPs are for...

Embodiment 3

[0039] Example 3 Preparation of canine interferon alpha particle complex CaIFNα-NPs encapsulating free canine interferon alpha

[0040] Take 1 ml of the above PGA-PAE material, slowly drop it into 1 ml of 0.4 mg / ml free canine interferon alpha aqueous solution, and mix to obtain a white emulsion. The emulsion was centrifuged at 16000 rpm for 15 min. The pellet was separated from the supernatant. The pellet was resuspended with 2 ml of pure water and centrifuged again at 16000 rpm for 15 min. The precipitate was separated from the supernatant, and the precipitate was lyophilized to obtain CaIFNα-NPs.

[0041] Wherein, the sequence of free canine interferon alpha is shown in SEQ ID No:2.

[0042] To verify whether free canine interferon alpha was encapsulated into particles and to calculate the encapsulation rate of free canine interferon alpha, CaIFNα-NPs were cleaved with 4% sodium dodecyl sulfonate solution. Since CaIFNα-NPs are formed by the amphiphilic self-polymerizati...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a canine interferon alpha particle compound CaIFN alpha-NPa and a preparation method thereof. The compound comprises a gamma-polyglutamic acid-phenylalanine shell and canine interferon alpha wrapped in the shell and is formed by assembling the gamma-polyglutamic acid-phenylalanine shell and the canine interferon alpha through a self-polymerization process. The invention also discloses application of the canine interferon alpha particle compound in the preparation of canine antiviral drugs and an antiviral composition. The canine interferon alpha particle compound is high in wrapping rate, free of toxic and side effects and good in biocompatibility, can be used for retarding enzymatic degradation to realize the drug effect slow-release effect, is simple and easy to operate, low in cost and suitable for large-scale production, and has favorable application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a canine interferon alpha particle complex, a preparation method and application thereof, and an antiviral composition. Background technique [0002] At present, the number of dogs is increasing, but the incidence of canine diseases, especially viral diseases, is increasing, which often leads to the death of dogs and causes spiritual and economic losses to humans. Canine interferon alpha is widely used in the treatment of canine viral diseases due to its broad antiviral activity. However, the canine interferon alpha preparations currently on the market need to be administered daily for 2-4 weeks as a course of treatment. Daily dosing and long periods of time are not only painful for sick dogs, but also increase the mental and economic burden of the owner, and also require a lot of drugs. This status quo is mainly due to the short duration of activity of the existin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/21A61K47/34A61K9/16A61P31/12
Inventor 杨芳黄静潘盈盈章华胜严文娟谭士明陈亚州吴自荣
Owner EAST CHINA NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap